Results 81 to 90 of about 11,456 (188)

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Canagliflozin: a novel treatment option for type 2 diabetes

, 2013
Eric Dietrich,1 Jason Powell,2 James R Taylor2 1University of Florida College of Medicine, Department of Community Health and Family Medicine, 2University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research ...
Taylor JR, Powell J, Dietrich E
core  

Canagliflozin and heart failure in Type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) [PDF]

, 2018
BACKGROUND : Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure and cardiovascular death overall, in those with and without a baseline ...
Figtree, Gemma, Matthews, David R., Barrett, TD, Perkovic, Vlado, Wayne Shaw, Bruce Neal, Perkovic, Vlado,, Rådholm, Karin, Fulcher, Greg,, Solomon, Scott D., Scott D. Solomon, De Zeeuw, D, Desai, M, Karin Rådholm, Figtree, Gemma,, Shaw, Wayne,, Mehul Desai, Neal, Bruce, Matthews, David R.,, Perkovic, V ; https://orcid.org/, Mahaffey, Kenneth W.,, Desai, Mehul, Shaw, W, Rådholm, K, Shaw, Wayne, Barrett, Terrance D.,, Vlado Perkovic, Neal, Bruce,, Neal, B ; https://orcid.org/, Matthews, David R, Figtree, G, Rådholm, Karin,, Gemma Figtree, Solomon, Scott D.,, Dick de Zeeuw, Solomon, Scott D, Terrance D. Barrett, de Zeeuw, Dick; id_orcid, Fulcher, Greg, David R. Matthews, Fulcher, G, Barrett, Terrance D, de Zeeuw, Dick,, Solomon, SD, Mahaffey, KW, Matthews, DR, Mahaffey, Kenneth W, de Zeeuw, Dick, Desai, Mehul,, Kenneth W. Mahaffey, Mahaffey, Kenneth W., Barrett, Terrance D., Greg Fulcher   +52 more
core   +2 more sources

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus

Journal of Clinical & Translational Endocrinology, 2014
Aim: To evaluate the efficacy/safety of canagliflozin twice daily (BID) compared with placebo in patients with type 2 diabetes mellitus (T2DM) on metformin.
Rong Qiu, MD, PhD, George Capuano, PhD, Gary Meininger, MD   +2 more
doaj   +1 more source

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aim Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD. Methods We conducted
Leandra Serio, Michele Rossi, Amir Askarinejad, Enrico Tartaglia, Tommaso Bucci, Enrica Marrone, Dinesh K. Kalra, Claudio Ferri, Gregory Y. H. Lip   +8 more
wiley   +1 more source

Canagliflozin-induced pancreatitis: a rare side effect of a new drug

, 2015
Mudit Chowdhary,1 Ahmad A Kabbani,1 Akansha Chhabra21Department of Internal Medicine, Mercer University School of Medicine, Macon, GA, USA; 2Department of Internal Medicine, New York University Langone Medical Center, New York, NY, USAAbstract: Acute ...
Kabbani AA, Chowdhary M, Chhabra A
core  

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

, 2016
Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers renoprotection.
Hiddo J. L. Heerspink, Desai, Mehul, Mehul Desai, Heerspink, Hiddo J. L., Perkovic, Vlado, Gary Meininger, Dainius Balis, Balis, Dainius, Meininger, Gary, Jardine, Meg, Meg Jardine, Vlado Perkovic   +11 more
core   +1 more source